Ind-Swift Limited (NSE:INDSWFTLTD)
India · Delayed Price · Currency is INR 16.12
-0.24 (-1.47%)
Aug 6, 2025, 2:15 PM IST
Ind-Swift Revenue
In the fiscal year ending March 31, 2025, Ind-Swift had annual revenue of 5.15B INR with 2.54% growth. Ind-Swift had revenue of 1.45B in the quarter ending March 31, 2025, with 6.98% growth.
Revenue
5.15B
Revenue Growth
+2.54%
P/S Ratio
0.17
Revenue / Employee
4.89M
Employees
1,054
Market Cap
892.09M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 5.15B | 127.66M | 2.54% |
| Mar 31, 2024 | 5.02B | 913.35M | 22.22% |
| Mar 31, 2023 | 4.11B | 93.73M | 2.33% |
| Mar 31, 2022 | 4.02B | 420.91M | 11.70% |
| Mar 31, 2021 | 3.60B | 227.98M | 6.77% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 537.77B |
| Divi's Laboratories | 93.60B |
| Cipla | 274.80B |
| Mankind Pharma | 129.10B |
| Apollo Hospitals Enterprise | 217.94B |
| Zydus Lifesciences | 232.42B |
| Fortis Healthcare | 77.86B |
| Aurobindo Pharma | 317.24B |